Search
Eikon Therapeutics Ord Shs
EIKNAdd to Watchlist
5.980USD
-0.060-0.99%
Close 11-13 16:00（ET）
323.94MMarket Cap
LossP/E TTM
EIKN Analyst Recommendation Trends
In the current month, EIKN has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. EIKN average Analyst price target in the last month is 23.400.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
1
1
1
1
1
0
4
4
4
4
4
4
4
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
6
6
6
6
6
6
6
0
Financial Forecasting
Based on analysts' estimates, EIKN EPS is projected to reach -1.806 in FY2026Q4, following reported EPS of -1.590 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-1.74
-1.58
-1.70
-1.81
-1.80
Actual
-2.46
-1.63
-1.59
--
--
Surprise
-41.15%
-3.02%
+6.46%
--
--
FAQs
How have Eikon Therapeutics Ord ShsEIKN's recent earnings per share performed?
The market expectation was USD -1.59, while Eikon Therapeutics Ord ShsEIKN's earnings per share (EPS) for the previous quarter was USD -1.63. EPS for the next quarter is expected at USD -1.81.
What is the analyst rating for Eikon Therapeutics Ord Shs?
Based on the ratings of Eikon Therapeutics Ord Shs's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.